514 related articles for article (PubMed ID: 9122738)
1. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for epithelial ovarian carcinoma.
Christian MC; Trimble EL
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel (Taxol) therapy in ovarian carcinoma.
Caldas C; McGuire WP
Semin Oncol; 1993 Aug; 20(4 Suppl 3):50-5. PubMed ID: 7688146
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
6. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
7. One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Greco FA; Hainsworth JD
Semin Oncol; 1995 Jun; 22(3 Suppl 6):118-23. PubMed ID: 7597427
[TBL] [Abstract][Full Text] [Related]
8. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma.
McGuire WP
Gynecol Oncol; 1993 Oct; 51(1):78-85. PubMed ID: 7902314
[TBL] [Abstract][Full Text] [Related]
9. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support.
Shpall EJ; Jones RB; Bearman SI; Purdy MP
Gynecol Oncol; 1994 Sep; 54(3):357-61. PubMed ID: 8088613
[TBL] [Abstract][Full Text] [Related]
10. Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Reichman B; Markman M; Hakes T; Rubin S; Jones W; Curtin J; Barakat R; Almadrones L; Lewis JL; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):30-3. PubMed ID: 8349161
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
12. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Hawkins MJ
Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
[TBL] [Abstract][Full Text] [Related]
13. Taxol in epithelial ovarian cancer.
Caldas C; McGuire WP
J Natl Cancer Inst Monogr; 1993; (15):155-9. PubMed ID: 7517152
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
Gregory RE; DeLisa AF
Clin Pharm; 1993 Jun; 12(6):401-15. PubMed ID: 7691462
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
[TBL] [Abstract][Full Text] [Related]
16. Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Markman M; Hakes T; Reichman B; Barakat R; Curtin J; Jones W; Lewis JL; Rubin S; Almadrones L; Hoskins W
Semin Oncol; 1992 Dec; 19(6 Suppl 14):25-7. PubMed ID: 1488652
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced epithelial ovarian cancer.
Ozols RF
Hematol Oncol Clin North Am; 1992 Aug; 6(4):879-94. PubMed ID: 1500391
[TBL] [Abstract][Full Text] [Related]
19. [A phase II study of BMS-181339 in patients with ovarian cancer. BMS-181339 Ovarian Cancer Study Group].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Nozawa S; Taketani Y; Terashima Y
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2461-9. PubMed ID: 7944492
[TBL] [Abstract][Full Text] [Related]
20. Taxol: initial Israeli experience with a novel anticancer agent.
Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
